42.44
+1.73(+4.25%)
Currency In USD
| Previous Close | 40.71 |
| Open | 40.26 |
| Day High | 42.55 |
| Day Low | 40.06 |
| 52-Week High | 45.56 |
| 52-Week Low | 14.8 |
| Volume | 708,425 |
| Average Volume | 1M |
| Market Cap | 3.18B |
| PE | -20.7 |
| EPS | -2.05 |
| Moving Average 50 Days | 40.39 |
| Moving Average 200 Days | 29.48 |
| Change | 1.73 |
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
GlobeNewswire Inc.
Sep 05, 2025 11:00 AM GMT
- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) treatment -- 90% of 12-month r
CG Oncology Completes Enrollment in PIVOT-006
GlobeNewswire Inc.
Sep 03, 2025 12:00 PM GMT
– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the largest randomized phase 3 studies in this patient population will encompass broadest range of patient types per AUA/SUO Guid
CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 29, 2025 12:00 PM GMT
IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder